BioPharma Resources

Drug Trial Radar · NCT00000620

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Last checked: Nov 19, 2026Latest source record: Nov 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 10,251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,251

Actual

Start

Sep 1999

Primary completion

Jun 2009

Study completion Dec 2012

Sponsor

Sponsor type
NIH
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute on Aging (NIA); National Eye Institute (NEI); Centers for Disease Control and Prevention
First posted
Oct 28, 1999

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 40 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.

Conditions

  • Atherosclerosis
  • Cardiovascular Diseases
  • Hypercholesterolemia
  • Hypertension
  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus
  • Coronary Disease

Interventions

  • Anti-hyperglycemic AgentsDrug

    Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control \<6%; standard control 7.0-7.9%).

  • Anti-hypertensive AgentsDrug

    Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control \<120 mm Hg; standard control \<140 mm Hg).

  • Blinded fenofibrate or placebo plus simvastatinDrug

    Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.Time frame: 4.9 years
  2. First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.Time frame: 4.7 years
  3. First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.Time frame: 4.7 years

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Minneapolis Medical Research Foundation

    Minneapolis, Minnesota

  • Columbia University

    New York, New York

  • Wake Forest University

    Winston-Salem, North Carolina

  • Case Western Reserve University

    Cleveland, Ohio

  • Veterans Affairs

    Memphis, Tennessee

  • University of Washington

    Seattle, Washington

  • McMaster University

    Hamilton, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.